Windlas Biotech IPO Subscription Day-1
Last Updated: 13th December 2022 - 11:27 pm
The Rs.401.54 crore IPO of Windlas Biotech, consisting of Rs.165 crore fresh issue and Rs.236.54 crore OFS, has gradually built on the response from retail investors on Day-1. As per the combined bid details put out by the BSE, Windlas Biotech IPO was subscribed 3.17X overall, with bulk of the demand coming from the retail segment followed by the HNI segment.
As of close of 04 August, out of the 61.36 lakh shares on offer in the IPO, Windlas Biotech saw applications for 193.37 lakh shares. This implies an overall subscription of 3.15X. The granular break-up of subscriptions were tilted in favour of retail investors but HNI portion and QIB bids would typically come in on the last day.
Windlas Biotech IPO Subscription Day 1
Category | Subscription Status |
Qualified Institutional (QIB) | 0.00 Times |
Non-Institutional (NII) | 0.34 Times |
Retail Individual | 6.15 Times |
Total | 3.17 Times |
QIB Portion
The QIB portion did not open its account at the end of Day-1. On 03 August, Windlas Biotech did an anchor placement of Rs.120.46 crore to 22 QIB investors like Macquarie, Optimix, Invesco, Kubera, Elara, Avendus etc. QIB portion did not see any action on Day-1.
HNI Portion
The HNI portion got subscribed 0.34X (getting applications for 4.435 lakh shares against the quota of 13.238 lakh shares). Of course, funded applications and corporate applications, will come in on the last day.
Retail Portion
The real story was the retail portion, which is already subscribed 6.15 times at the end of Day-1, showing strong retail appetite. Among retail investors; out of the 30.89 lakh shares on offer, valid bids were received for 188.94 lakh shares, of which bids for 147.96 lakh shares were at the cut-off price. The IPO is priced in the band of (Rs.448-Rs.460) and will close for subscription on Friday, 06 August.
Trending on 5paisa
04
5paisa Research Team
Discover more of what matters to you.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.